November 12, 2019
Eagle Pharmaceuticals Reports Third Quarter 2019 Results
— Net loss of $0.17 per basic and diluted share and adjusted non-GAAP net income of $0.27 per basic and…
Pharmaceuticals, Biotechnology and Life Sciences
— Net loss of $0.17 per basic and diluted share and adjusted non-GAAP net income of $0.27 per basic and…
WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today provided an update on the Company’s program…
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today that positive results from a Phase 3 investigational study of tofacitinib in…
ZULRESSO™ (brexanolone) CIV injection revenues of $1.5M in third quarter Enrollment completed in SAGE-217 Phase 3 MOUNTAIN and SHORELINE studies…
ZULRESSO™ (brexanolone) CIV injection revenues of $1.5M in third quarter Enrollment completed in SAGE-217 Phase 3 MOUNTAIN and SHORELINE studies…
Company to provide update on status of ongoing Phase 2 clinical trial in eosinophilic asthma PITTSBURGH–(BUSINESS WIRE)–#Knoppbio–Knopp Biosciences LLC, a…
Company to provide update on status of ongoing Phase 2 clinical trial in eosinophilic asthma PITTSBURGH–(BUSINESS WIRE)–#Knoppbio–Knopp Biosciences LLC, a…
DUBLIN–(BUSINESS WIRE)–The “Cubicin – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Cubicin Drug Insight, 2019 highlights the…
DUBLIN–(BUSINESS WIRE)–The “Cubicin – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Cubicin Drug Insight, 2019 highlights the…
DUBLIN–(BUSINESS WIRE)–The “Adlyxin – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Adlyxin Drug Insight, 2019 highlights the…